The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC or novel ADC projects in clinical or preclinical research stage.
ADC Therapeutics SA ... ADC Therapeutics SA ... Thank you for your ongoing support of and interest in ADC Therapeutics SA ... ADC Therapeutics SA ... ADC Therapeutics SA (the "Company") is soliciting proxies for the Annual Meeting ... ADC Therapeutics SA.
A Pioneer and Leader in ADCs ... Commercial-stage pioneer in the field of ADCs, with specialized end-to-end capabilities from discovery to commercialization ... Focused ADCPortfolio in Hematology and Solid Tumors ... ADCs / mAbs.
Alfa Cytology has officially released its antibody-drug conjugates (ADCs) development services which demonstrates the dedication to fighting cancer through advanced treatment methods ... ADCs development ...
SHANGHAI, April 2, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code.